Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Y F So

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
CJC Open|June 25, 2021
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in CanadaMarie Lordkipanidzé, Guillaume Marquis-Gravel, Jean-François Tanguay, et al.
Clinical Chemistry|August 15, 2015
Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?Michael J Knauer, Eleftherios P Diamandis, Jean-Sebastien Hulot, et al.
The Canadian Journal of Cardiology|December 3, 2014
Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermiaRohit Moudgil, Haytham Al-Turbak, Christina Osborne, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|July 13, 2005
Thrombus of the ascending aorta: a rare cause of myocardial infarctionAllan L Wolfsohn, Derek Y F So, Kwan Chan, et al.
BMJ Open|June 19, 2019
Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic reviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
The Journal of Invasive Cardiology|July 7, 2010
Lesion characteristics and coronary stent selection with computed tomographic coronary angiography: a pilot investigation comparing CTA, QCA and IVUSMalek Kass, Christopher A Glover, Marino Labinaz, et al.
The Canadian Journal of Cardiology|August 5, 2019
Optimal Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: An Umbrella ReviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
BMJ Open|April 6, 2017
Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella reviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
Platelets|April 15, 2021
Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparisonCole R Clifford, Richard G Jung, Benjamin Hibbert, et al.
Journal of Clinical Medicine|January 30, 2020
Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y<sub>12</sub> Inhibition-Insights for Multi-Center TrialsJean-Christophe Bélanger, Fabio Luiz Bandeira Ferreira, Mélanie Welman, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
CJC Open|June 25, 2021
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in CanadaMarie Lordkipanidzé, Guillaume Marquis-Gravel, Jean-François Tanguay, et al.
Clinical Chemistry|August 15, 2015
Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?Michael J Knauer, Eleftherios P Diamandis, Jean-Sebastien Hulot, et al.
The Canadian Journal of Cardiology|December 3, 2014
Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermiaRohit Moudgil, Haytham Al-Turbak, Christina Osborne, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|July 13, 2005
Thrombus of the ascending aorta: a rare cause of myocardial infarctionAllan L Wolfsohn, Derek Y F So, Kwan Chan, et al.
BMJ Open|June 19, 2019
Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic reviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
The Journal of Invasive Cardiology|July 7, 2010
Lesion characteristics and coronary stent selection with computed tomographic coronary angiography: a pilot investigation comparing CTA, QCA and IVUSMalek Kass, Christopher A Glover, Marino Labinaz, et al.
The Canadian Journal of Cardiology|August 5, 2019
Optimal Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: An Umbrella ReviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
BMJ Open|April 6, 2017
Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella reviewJesse Elliott, Shannon E Kelly, Zemin Bai, et al.
Platelets|April 15, 2021
Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparisonCole R Clifford, Richard G Jung, Benjamin Hibbert, et al.
Journal of Clinical Medicine|January 30, 2020
Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y<sub>12</sub> Inhibition-Insights for Multi-Center TrialsJean-Christophe Bélanger, Fabio Luiz Bandeira Ferreira, Mélanie Welman, et al.
Pageof 5